Keyphrases
Acute Myeloid Leukemia
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
52%
Venetoclax
38%
Relapsed or Refractory
32%
Leukemia Patients
26%
Chemotherapy
25%
Intensive Chemotherapy
24%
Overall Survival
21%
Neutrophil Extracellular Traps
20%
Acute Lymphoblastic Leukemia
20%
Adult Patients
19%
Neutrophils
17%
Israel
17%
Complete Remission
17%
First Remission
16%
Newly Diagnosed
16%
Midostaurin
16%
Leukemia
14%
Hypomethylating Agents
14%
Myeloproliferative Neoplasms
13%
First Complete Remission
12%
Relapsed or Refractory Acute Myeloid Leukemia
12%
Lymphoma
11%
FLT3 mutation
11%
Oncology Patients
11%
Tyrosine Kinase Inhibitor
11%
Gilteritinib
11%
Late-onset Neutropenia
11%
Mixed-phenotype Acute Leukemia
11%
Blinatumomab
11%
Meta-analysis
11%
Systematic Meta-analysis
11%
FLAG-Ida
11%
Chronic Granulomatous Disease
11%
Graft-versus-host Disease (GvHD)
11%
Leukemia-lymphoma
11%
Older Adults
10%
Cytarabine
10%
Pretransplant
10%
Neutropenia
9%
Minimal Residual Disease
9%
Consolidation Chemotherapy
9%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
9%
Induction Therapy
9%
Monotherapy
8%
Human Telomerase Reverse Transcriptase (hTERT)
8%
Median Overall Survival
8%
Bacteremia
8%
Azacitidine
8%
Thrombosis
8%
Medicine and Dentistry
Acute Myeloid Leukemia
90%
Venetoclax
34%
Hematopoietic Cell
31%
Cell Transplantation
31%
Overall Survival
25%
Acute Lymphoblastic Leukemia
21%
Diseases
19%
Neutropenia
16%
Neutrophil
16%
Acute Myelogenous Leukemia
15%
Hypomethylating Agent
14%
Bloodstream Infection
14%
Infection
13%
Systematic Review
13%
Myelodysplastic Syndrome
12%
Malignant Neoplasm
12%
Azacitidine
12%
Retrospective Study
12%
Meta-Analysis
11%
Chronic Granulomatous Disease
11%
Leukemia
11%
Cytarabine
10%
Platelet
10%
Graft Versus Host Reaction
9%
Consolidation Chemotherapy
9%
Hematopoietic Stem Cell Transplantation
9%
Extracellular Trap
8%
Midostaurin
8%
Rituximab
8%
Minimal Residual Disease
8%
Gilteritinib
7%
Maintenance Therapy
7%
Anemia
7%
Telomerase Reverse Transcriptase
7%
Photopheresis
7%
Acute Leukemia
7%
Salvage Therapy
7%
Pediatrics
7%
Randomized Controlled Trial
7%
Neoplasm
7%
Diffuse Large B-Cell Lymphoma
7%
Non-Hodgkin Lymphoma
7%
Non-Relapse Mortality
6%
Infectious Complication
6%
Drug Megadose
6%
Allograft
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Chronic Graft Versus Host Disease
5%
Febrile Neutropenia
5%
Conditioning
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
73%
Chemotherapy
38%
Venetoclax
34%
Remission
28%
Overall Survival
24%
Acute Lymphoblastic Leukemia
17%
Neutropenia
16%
Cytarabine
13%
Diseases
13%
Leukemia
12%
Protein Tyrosine Kinase Inhibitor
12%
Azacitidine
12%
Rituximab
12%
Malignant Neoplasm
11%
Acute Leukemia
11%
Blinatumomab
11%
Gilteritinib
11%
Bloodstream Infection
10%
Randomized Controlled Trial
9%
Graft Versus Host Reaction
9%
Monotherapy
8%
Midostaurin
8%
Retrospective Study
7%
Methotrexate
7%
C Reactive Protein
7%
Thrombopoietin Receptor
7%
Chimeric Antigen Receptor
7%
Infection
7%
Adverse Event
6%
Neoplasm
6%
Chronic Graft Versus Host Disease
6%
Infectious Complication
6%
Febrile Neutropenia
5%
Telomerase Reverse Transcriptase
5%
Minimal Residual Disease
5%
Cohort Study
5%
Myeloproliferative Neoplasm
5%
Cardiotoxicity
5%
Antiinfective Agent
5%